新型癌症免疫疗法的 cardiotoxicity(心脏毒性)
本综述讨论免疫检查点抑制剂(ICI)、嵌合抗原受体(CAR)T 细胞疗法和双特异性 T 细胞衔接器相关心脏毒性的流行病学、机制与处理。ICI 相关心肌炎最受关注且致死率接近 50%;CAR T 细胞疗法的高级别细胞因子释放综合征(CRS)可致心律失常、血流动力学障碍和心肌病,需快速免疫抑制治疗。
要点
- ICI 相关心脏毒性包括心肌炎、心包炎、动脉粥样硬化、心律失常和血管炎。
- ICI 相关心肌炎最受关注且可能致命,死亡率接近 50%。
- CAR T 细胞疗法的高级别 CRS 可致心律失常、血流动力学障碍和心肌病。
核心结论
- 免疫治疗相关心血管毒性虽不常见,但可显著增加疾病和死亡风险,快速免疫抑制治疗有益。
研究设计与样本
- 综述,讨论 ICI、CAR T 细胞疗法和双特异性 T 细胞衔接器相关心脏毒性的现有文献。
主要发现
- ICI 相关心脏毒性包括心肌炎、心包炎、动脉粥样硬化、心律失常和血管炎。
- ICI 相关心肌炎最受关注且可能致命,死亡率接近 50%。
- 长期使用 ICI 与动脉粥样硬化斑块免疫反应失调相关,并 linked to 动脉粥样硬化早期进展和心肌梗死。
- CAR T 细胞疗法可引发 CRS,高级别 CRS 导致心律失常、血流动力学障碍和心肌病。
关键数值与推荐
- ICI 相关心肌炎死亡率接近 50%。
- ICI 相关心脏毒性治疗包括糖皮质激素免疫抑制和支持治疗。
- CAR T 细胞疗法相关 CRS 治疗使用白细胞介素-6 抑制剂和糖皮质激素,与改善结局相关。
临床怎么用
- 使用 ICI、CAR T 细胞疗法和双特异性 T 细胞衔接器时需密切监测心脏毒性。
- 对免疫治疗相关心血管毒性应快速给予免疫抑制治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy revolutionised oncology by harnessing the native immune system to effectively treat a wide variety of malignancies even at advanced stages. Off-target immune activation leads to immune-related adverse events affecting multiple organ systems, including the cardiovascular system. In this review, we discuss the current literature describing the epidemiology, mechanisms and proposed management of cardiotoxicities related to immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers. ICIs are monoclonal antibody antagonists that block a co-inhibitory pathway used by tumour cells to evade a T cell-mediated immune response. ICI-associated cardiotoxicities include myocarditis, pericarditis, atherosclerosis, arrhythmias and vasculitis. ICI-associated myocarditis is the most recognised and potentially fatal cardiotoxicity with mortality approaching 50%. Recently, ICI-associated dysregulation of the atherosclerotic plaque immune response with prolonged use has been linked to early progression of atherosclerosis and myocardial infarction. Treatment strategies include immunosuppression with corticosteroids and supportive care. In CAR T-cell therapy, autologous T cells are genetically engineered to express receptors targeted to cancer cells. While stimulating an effective tumour response, they also elicit a profound immune reaction called cytokine release syndrome (CRS). High-grade CRS causes significant systemic abnormalities, including cardiovascular effects such as arrhythmias, haemodynamic compromise and cardiomyopathy. Treatment with interleukin-6 inhibitors and corticosteroids is associated with improved outcomes. The evidence shows that, although uncommon, immunotherapy-related cardiovascular toxicities confer significant risk of morbidity and mortality and benefit from rapid immunosuppressive treatment. As new immunotherapies are developed and adopted, it will be imperative to closely monitor for cardiotoxicity.
引用
- Stein-Merlob AF, Rothberg MV, Ribas A, et al. Cardiotoxicities of novel cancer immunotherapies. Heart. 2021. PMID: 33722826. doi:10.1136/heartjnl-2020-318083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。